Strategic Financial Concepts LLC Purchases Shares of 176,485 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Strategic Financial Concepts LLC bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 176,485 shares of the biopharmaceutical company's stock, valued at approximately $41,529,000. Alnylam Pharmaceuticals makes up approximately 1.3% of Strategic Financial Concepts LLC's investment portfolio, making the stock its 5th largest holding. Strategic Financial Concepts LLC owned about 0.14% of Alnylam Pharmaceuticals as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Huntington National Bank lifted its position in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 45 shares in the last quarter. Hollencrest Capital Management bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $29,000. R Squared Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $33,000. Washington Trust Advisors Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $42,000. Finally, True Wealth Design LLC increased its holdings in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 153 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Insider Activity at Alnylam Pharmaceuticals

In other news, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the transaction, the chief financial officer now owns 32,786 shares in the company, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the business's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the sale, the chief marketing officer now owns 17,457 shares in the company, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,356 shares of company stock valued at $22,498,551 over the last 90 days. Insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

Several research firms have issued reports on ALNY. Scotiabank reduced their price objective on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating on the stock in a report on Friday, February 14th. Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a "buy" rating in a report on Tuesday. Morgan Stanley boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Barclays raised their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a research note on Friday, November 1st. Finally, Needham & Company LLC reissued a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $299.48.

Alnylam Pharmaceuticals Price Performance

ALNY traded up $0.51 on Wednesday, reaching $250.51. The stock had a trading volume of 766,476 shares, compared to its average volume of 693,993. The firm has a 50-day moving average of $253.89 and a 200-day moving average of $263.20. The company has a market capitalization of $32.43 billion, a price-to-earnings ratio of -115.44 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.94 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.